Overview and recent advances in the treatment of neuroblastoma (Q30238693)

12 June 2017

title

Overview and recent advances in the treatment of neuroblastoma (English)

1 reference

12 June 2017

1 reference

Sarah B Whittle

1

1 reference

12 June 2017

Valeria Smith

2

1 reference

12 June 2017

Erin Doherty

3

1 reference

12 June 2017

Sibo Zhao

4

1 reference

12 June 2017

Scott McCarty

5

1 reference

12 June 2017

Peter E Zage

6

1 reference

12 June 2017

publication date

1 February 2017

1 reference

Expert Review of Anticancer Therapy

12 June 2017

published in

1 reference

12 June 2017

volume

17

1 reference

12 June 2017

issue

4

1 reference

12 June 2017

page(s)

369-386

1 reference

International variations in the incidence of neuroblastoma.

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The epidemiology of neuroblastoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Neuroblastoma: paradigm for precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Neuroblastoma Screening at One Year of Age

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Screening of infants and mortality due to neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Screening for neuroblastoma: a resurrected idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Maternal medication use and neuroblastoma in offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Day care, childhood infections, and risk of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Systematic Review of Chromium and Nickel Exposure During Pregnancy and Impact on Child Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Germline PHOX2B mutation in hereditary neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Familial occurrence of neuroblastoma, von Recklinghausen's neurofibromatosis, Hirschsprung's agangliosis and jaw-winking syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Emergence of new ALK mutations at relapse of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Copy number variation at 1q21.1 associated with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus–ataxia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

New aspects of neuroblastoma treatment: ASPHO 2011 symposium review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The role of surgery in stage IV neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Clinical results of proton beam therapy for advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Stem cell transplantation for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Factors influencing survival in children with recurrent neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Functional significance of Aurora kinase A in centrosome amplification and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Antitrypanosomal Therapy for Chronic Chagas' Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

FCGR2APolymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

NK Cell immunotherapy for high‐risk neuroblastoma relapse after haploidentical HSCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term complications in survivors of advanced stage neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Second malignancies in patients with neuroblastoma: the effects of risk-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1285230

10.1080/14737140.2017.1285230

21 January 2018

Identifiers

DOI

1 reference

12 June 2017

1 reference